Cargando…
Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
Therapeutic repurposing emerged as an alternative to the traditional drug discovery and development model (DDD) of new molecular entities (NMEs). It was anticipated that by being faster, safer, and cheaper, the development would result in lower-cost drugs. As defined in this work, a repurposed cance...
Autores principales: | Gonzalez-Fierro, Aurora, Romo-Pérez, Adriana, Chávez-Blanco, Alma, Dominguez-Gomez, Guadalupe, Duenas-Gonzalez, Alfonso |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097740/ https://www.ncbi.nlm.nih.gov/pubmed/36884210 http://dx.doi.org/10.1007/s40261-023-01251-0 |
Ejemplares similares
-
HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004) -
Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006) -
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012) -
A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020) -
Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)